Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.75 |
| ▸ | GLS | O94925 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601361 | 1.00 | DGAT1 (0.75) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| Bicarbonate SCHEMBL15655650 | 0.91 | DGAT1 (0.65) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL601432 | 0.86 | DGAT1 (1.00) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL603963 | 0.86 | DGAT1 (1.00) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL603170 | 0.84 | DGAT1 (0.75) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL603169 | 0.84 | DGAT1 (0.75) | DGAT1GLSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL601327 | 0.83 | DGAT1 (0.58) | DGAT1SMN1; SMN2 | |
| SCHEMBL601328 | 0.83 | DGAT1 (0.58) | DGAT1SMN1; SMN2 | |
| SCHEMBL601329 | 0.83 | DGAT1 (0.58) | DGAT1SMN1; SMN2 | |
| SCHEMBL601024 | 0.83 | DGAT1 (1.00) | DGAT1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | claimed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | claimed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | DGAT1 3495/4885GLS 181/4885SMN1; SMN2 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.